We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Galapagos Delivers Third Candidate Drug in GSK Alliance, Receives €5.7 Million

News   Feb 23, 2010

 
Galapagos Delivers Third Candidate Drug in GSK Alliance, Receives €5.7 Million
 
 
Advertisement
 

RELATED ARTICLES

Hydroxychloroquine and Lopinavir/Ritonavir Treatment Arms for COVID-19 Discontinued

News

The World Health Organization (WHO) has accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue hydroxychloroquine and lopinavir/ritonavir study arms.

READ MORE

Trial of Saliva Test for COVID-19 Launched

News

Scientists from the Innovative Genomics Institute (IGI), the same UC Berkeley group that rapidly popped up a state-of-the-art COVID-19 testing laboratory in March, are now trialing a quicker way to obtain patient samples: through saliva.

READ MORE

SARS-CoV-2 Immunity Likely To Be Higher Than Antibody Testing Has Shown

News

A recent study suggests that many people who contract SARS-CoV-2 but have mild or no clinical signs still develop so-called T-cell-mediated immunity to the virus, even in the absence of a positive antibody test. The researchers conclude that this is likely to mean that public immunity is probably higher than antibody testing has so far suggested.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Diagnostics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE